T-Cell Immune Monitoring Strategies: The Critical Role of ELISpot and FluoroSpot
- No Comments
In the development of biologics and advanced therapies, the industry has historically focused heavily on the humoral immune response. Screening for Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb) is a standard path for regulatory approval. However, for developers of Gene Therapies (AAV, Lentivirus) and complex biologics, ADA data only tells half the story. As highlighted […]
Read More